Romantowski Jan, Specjalski Krzysztof, Jakub Łata, Wasilewska Eliza, Chełmińska Marta, Jassem Ewa, Niedoszytko Marek
Department of Allergology, Medical University of Gdansk, Gdansk, Poland.
Postepy Dermatol Alergol. 2019 Dec;36(6):673-676. doi: 10.5114/ada.2018.80654. Epub 2019 Dec 30.
Allergen specific immunotherapy (AIT) is the only treatment modifying the course of the disease in patients allergic to airborne allergens. It has been proven to be effective in allergic populations, however individual patients vary in terms of response to the therapy.
To assess the factors that might affect the efficacy of AIT.
Patients treated with AIT for grass pollen or house dust mites were included. The efficacy of AIT was assessed with the use of Allergy Control Score (ACS), performed before and at least 1 year after AIT. The following variables were assessed as potential risk factors for a worse response to AIT: age, gender, type of allergy, type of allergen, type of vaccine, type of AIT and smoking history.
The study group consisted of 145 subjects.AIT was effective in the entire group; the mean ACS results decreased from 21.14 to 14.41 points (< 0.0001). No differences in efficacy in terms of assessed risk factors were found, except for smoking history (ACS change in the smoking group was smaller: from 21.8 to 18.1 points; = 0.09, OR = 0.323; 95% CI: 0.11-0.88; = 0.02).
Smoking history may affect AIT outcomes.
变应原特异性免疫疗法（AIT）是唯一一种能改变对空气传播变应原过敏患者疾病进程的治疗方法。已证实其在过敏人群中有效，但个体患者对该疗法的反应存在差异。
评估可能影响AIT疗效的因素。
纳入接受AIT治疗草花粉或屋尘螨过敏的患者。使用过敏控制评分（ACS）评估AIT疗效，在AIT治疗前及治疗至少1年后进行评分。评估以下变量作为AIT反应较差的潜在风险因素：年龄、性别、过敏类型、变应原类型、疫苗类型、AIT类型和吸烟史。
研究组由145名受试者组成。AIT在整个组中均有效；ACS平均结果从21.14分降至14.41分（<0.0001）。除吸烟史外，未发现评估的风险因素在疗效方面存在差异（吸烟组ACS变化较小：从21.8分降至18.1分；P = 0.09，OR = 0.323；95%CI：0.11 - 0.88；P = 0.02）。
吸烟史可能影响AIT治疗效果。
